Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT_2C,...

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• Viloxazine is recognized as a norepinephrine reuptake inhibitor for depression and ADHD.
• Emerging evidence suggests a more complex mechanism involving serotonin receptors.
• Previous studies indicated viloxazine's activity at 5-HT_2C, 5-HT_2B, and 5-HT₇ receptors.

Purpose of the Study:

• To characterize viloxazine's affinity and activity at the norepinephrine transporter (NET) and specific serotonin receptors.
• To elucidate how these interactions contribute to viloxazine's mechanism of action.
• To validate and expand upon prior research regarding viloxazine's pharmacology.

Main Methods:

• In vitro binding competition and functional assays were employed.
• Ex vivo receptor occupancy studies in rats were conducted.
• Viloxazine's activity was assessed at human NET and 5-HT_2C, 5-HT_2B, and 5-HT₇ receptors.

Main Results:

• Viloxazine demonstrated moderate binding affinity for NET and 5-HT_2C, 5-HT_2B, and 5-HT₇ receptors.
• Functional assays revealed viloxazine as a NET inhibitor, 5-HT_2C partial agonist, and 5-HT_2B/5-HT₇ antagonist.
• Clinically relevant concentrations showed high potential occupancy for NET, 5-HT_2C, 5-HT_2B, and significant occupancy for 5-HT₇ receptors.

Conclusions:

• Results confirm viloxazine's high NET occupancy and its actions as a partial agonist at 5-HT_2C and antagonist at 5-HT_2B/5-HT₇ receptors.
• Both NET inhibition and serotonin receptor modulation likely contribute to viloxazine's efficacy in ADHD treatment.
• This study enhances the understanding of viloxazine's pharmacodynamics and multimodal mechanism of action.